CSI Frankfurt 2019 - Home


June 26 – 29, 2019
Frankfurt, Germany

CSI Frankfurt 2019: Catheter Interventions in Congenital, Structural and Valvular Heart Disease - CSI 2019 CSI 2019 Catheter Interventions in Congenital, Structural and Valvular Heart Disease
CSI Frankfurt 2019
CSI Frankfurt 2019

Save the Date!
June 26 – 29, 2019 | Frankfurt, Germany
csi pfeil
Newsletter subscription

PodCase
of the Month  
RCA VENOUS BYPASS ANEURYSM
csi pfeil
watch now free of charge

Add to my calendar
CSI 2019 Congress overview Access CSI 2018 Scientific program Focus workshopsAvailable soon
Training hub Abstracts and cases Scientific faculty Attendee information Industry Impressions and references CSI@home Downloads Archive Event calendar Contact
Fontsize bigger
  CSI Frankfurt 2019: Catheter Interventions in Congenital, Structural and Valvular Heart Disease
CSI Frankfurt 2019: Catheter Interventions in Congenital, Structural and Valvular Heart Disease

CSI Focus Innovation - Scientific faculty

Your Faculty access


Board of Directors

Todd Brinton, MD

Stanford University
Stanford
USA

Board of Directors: Todd Brinton, MD
More

Todd Brinton, MD

Stanford University
Stanford, USA

Board of Directors: Todd Brinton, MD
Todd Brinton is a Clinical Associate Professor of Medicine (Cardiology) and Consulting Associate Professor of Bioengineering at Stanford University. He is an attending interventional cardiologist at both Stanford University Medical Center and the Palo Alto VA Medical Center. He has served as the Innovation Fellowship Director for Stanford Biodesign since 2005 and also co-directs the Stanford graduate course series in Biodesign Innovation.

Dr. Brinton lectures on strategies for innovation and serves as a mentor to innovation fellows, graduate students, and executives. His academic research focuses on the process of innovation for development of novel medical technologies. He specifically focuses on the integration of research and development for new technologies with the clinical strategy and pre-clinical evaluation. He has served as a clinical investigator for a number to studies of interventional-based therapies for chronic ischemia heart disease and heart failure.

Dr. Brinton completed his medicine, cardiology, and interventional cardiology training at Stanford University. He holds an MD from the Chicago Medical School and a BS in Bioengineering from the University of California, San Diego. He is Co-Founder and Board Director for Shockwave Medical and BioParadox, Inc., which are both venture-backed medical device companies in the cardiovascular space. He also serves on the board of directors of Qool Therapeutics and Infogard Laboratories. In addition, he serves on the advisory board of a number of early-stage medical device companies, where he focuses on clinical development and strategy. Prior to medical school, he was the Clinical Research Director for Pulse Metric, Inc., a venture-backed medical device start-up company.

Sameer Gafoor, MD

Swedish Heart and Vascular Institute; CardioVascular Center Frankfurt CVC
Seattle
USA

Board of Directors: Sameer  Gafoor, MD
More

Sameer Gafoor, MD

Swedish Heart and Vascular Institute; CardioVascular Center Frankfurt CVC
Seattle, USA

Board of Directors: Sameer  Gafoor, MD
Attending Physician

Dr. Sameer Gafoor is an attending physician at the CardioVascular Center (CVC) Frankfurt headed by Horst Sievert, MD. He obtained his medical degree from Northwestern University in the United States, followed by Internal Medicine Residency at University of michigan. His cardiology training started with Cardiovascular Disease Fellowship at Washington Hospital Center/Georgetown University and continued with Interventional Cardiology Fellowship at Emory University.

Following this training, he went on to complete an Advanced Fellowship in Neurovascular, Coronary, Structural Heart, and Peripheral Vascular Training at the CVC Frankfurt. He specializes in interventions and imaging for structural heart and peripheral vascular disease, as well as development and incorporation of new devices, technologies, and techniques for these and other indications.

Horst Sievert, MD

CardioVascular Center Frankfurt CVC
Frankfurt
Germany

Board of Directors: Horst Sievert, MD
More

Horst Sievert, MD

CardioVascular Center Frankfurt CVC
Frankfurt, Germany

Board of Directors: Horst Sievert, MD
Director and Founder of CVC Frankfurt

Specialist in Internal Medicine, Cardiology, Angiology, and Intensive Care

Medical degree from Johannes Gutenberg University Mainz and Johann Wolfgang Goethe University Frankfurt, Germany

Dr. Sievert has been the Principal Investigator of a number of clinical trials and has authored more than 130 manuscripts and 600 abstracts in peer reviewed journals, as well as 70 books and book contributions. He has also delivered more than 600 invited lectures around the world.
 
He has personally performed more than 16,000 PCIs and 6,000 peripheral angioplasties. However, his activity in the cath lab is focused on highly specialized non-coronary interventions for patients with congenital heart disease, carotid disease, or high risk of stroke, among other conditions. Dr Sievert was the first to close the left atrial appendage percutaneously. He has the largest experience worldwide in catheter closure of heart defects in adults and gets referrals from all over the world.

Co-Directors

Yuval Binur

Arsuf Partners
Tel Aviv, Israel; New York, USA
Shenzhen, China

Co-Directors: Yuval Binur
More

Yuval Binur

Arsuf Partners
Tel Aviv, Israel; New York, USA, Shenzhen, China

Co-Directors: Yuval Binur
Yuval Binur, Ph.D. is a Managing Partner of Orchestra. He has over 29 years of venture capital experience in the United States, Europe and Israel. Dr. Binur is a co-founder of Accelerated Technologies, Inc. and has served as its Chairman of the Board since its inception in 2001. From 1994 until 2004, he was founding Managing Partner of Medica, a global health care and life sciences venture capital fund operating from Israel. In this capacity, Dr. Binur helped raise Medica's first two venture funds and lead the deployment of approximately $140 million in investments into early stage healthcare technology companies. In 2000, he co-founded and led the financing for PVT, an AT I Portfolio company and the pilot for the Orchestra Strategy. In 2001, he co-founded ATI, and in 2003 he began devoting his full time to his role as Chairman of ATI after the Medica II fund was fully invested.

Dr. Binur participated actively in the sourcing, due diligence, deal structuring, investment execution and monitoring of all of the AT I Portfolio companies. He is currently a director of Mitralign, Vital Access and is also a director of SuperDimension, Ltd., a pioneer in the area of interventional pulmonology. For nine years prior to co-founding Medica, Dr Binur was a Member of Adler & Co., a major U.S. venture capital firm based in New York. He has been a board member of 48 venture-backed companies in the areas of medical technology and devices, pharmaceuticals, software and electronics. Dr. Binur holds a B.Sc. degree in electrical engineering from the Technion Institute in Israel and a Ph.D. degree in physics from MIT/Tel Aviv University.

Kathleen Marshall

Maxis Medical LLC
San Jose / Frankfurt
USA / Germany

Co-Directors: Kathleen Marshall
More

Kathleen Marshall

Maxis Medical LLC
San Jose / Frankfurt, USA / Germany

Co-Directors: Kathleen Marshall
Kathleen Marshall created MAXIS, LLC, in 2002 after nearly twenty years as a significant strategic contributor to the overall success of multiple medical device start-up companies. She holds a BA from Amherst College and a MS in Regulatory Affairs from Northeastern University. She is an experienced senior executive, skilled in clinical research, market development and commercialization of new medical technology. During her career in medical device start-ups, she has established a proven track record in conducting international clinical studies, building global markets, branding emerging technologies and leading start-up ventures. She has successfully established and managed teams that have created lasting clinical value and financial returns. She holds dual citizenship in the USA and Ireland.

Holly Whitin, MD

Maxis Medical
San Jose / Frankfurt am Main
USA / Germany

Co-Directors: Holly Whitin, MD
More

Holly Whitin, MD

Maxis Medical
San Jose / Frankfurt am Main, USA / Germany

Co-Directors: Holly Whitin, MD
Holly Whitin has more than 30 years’ experience in the market development and launch of innovative technologies in interventional cardiology and structural heart disease, including two transformational and disruptive platforms: angioplasty and transcatheter aortic valves. Her primary focus has been on Europe and Asia. She has been fundamental in bringing KOL advisory boards together and building multidisciplinary teams to accelerate clinical trial enrollment, efficient resource utilization and market adoption. Holly holds a BA from Swarthmore College and an MBA from the Darden School (U.Va.) She has worked in the medical device & pharmaceutical industry since the 1980’s. Ms. Whitin is a U.S. citizen and currently resides in Switzerland. She is fluent in English and French and is conversational in German. She has lived in several other countries, including The Netherlands, Belgium, Germany and Japan.

Faculty

Invited faculty will be available soon.


CSI   CSI
Contact Data Privacy Imprint Home Visit us on Facebook Visit us on Twitter